Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Investment analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $176.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 38.50% from the company’s current price.

Several other brokerages have also weighed in on AXSM. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. HC Wainwright upped their target price on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Finally, Leerink Partners upped their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.87.

Axsome Therapeutics Trading Up 20.2 %

Shares of Axsome Therapeutics stock opened at $127.08 on Tuesday. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $132.25. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company’s 50-day simple moving average is $94.72 and its 200-day simple moving average is $91.78. The firm has a market cap of $6.16 billion, a price-to-earnings ratio of -19.46 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the previous year, the business posted ($1.32) earnings per share. As a group, equities research analysts anticipate that Axsome Therapeutics will post -4.7 earnings per share for the current year.

Institutional Investors Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the business. Assetmark Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $64,000. KBC Group NV grew its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares in the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Axsome Therapeutics during the 3rd quarter valued at $200,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.